CDSCO Approves India's First Dengue Vaccine, Strengthening National Dengue Prevention Efforts

The Central Drugs Standard Control Organisation (CDSCO) has granted marketing authorisation to the Dengue Tetravalent Vaccine (Live, Attenuated) – Qdenga®, manufactured by Takeda GmbH and to be imported by Takeda Biopharmaceuticals India. The vaccine, a recombinant live‑attenuated tetravalent product produced in Vero cells, is approved for individuals aged 4–60 years with a two‑dose schedule (0 and 3 months). It has received regulatory approval in 42 countries, WHO pre‑qualification and more than 24 million doses have been distributed globally. The approval follows a comprehensive evaluation under the Drugs and Cosmetics Act, 1940 and is intended to complement existing vector‑control and surveillance measures under the National Vector Borne Disease Control Programme.